home contact company.overview news sitemap print


NMI TT GmbH

NMI-TT Contact Person

Markwiesenstr. 55
72770 Reutlingen
Germany

Ion Channel

News

page: 1 of 9 | items: 1 to 3 | next

02.05.2016
Press Release: Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for the treatment of Fragile X Syndrome


Cambridge/UK and Berlin/Germany, May 2, 2016 – Sentinel Oncology
and NMI TT Pharmaservices today announced that they have received grant funding for the development of a companion diagnostic to compliment the ongoing drug development activities within Sentinel Oncology for the treatment of the Fragile X Syndrome (FXS), a genetically inherited orphan disease that manifests itself in intellectual disability, for which no treatments are currently available. [more...]

09.01.2016
Product Launch: new Cav1.2 cell line
Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension.
[more...]

14.12.2015
Technician position in Berlin
We have recently opened a new branch of NMI TT Pharmaservices, based on the campus of Bayer HealthCare in Berlin.
[more...]

 

top

NMI TT a business unit of NMI